Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Studying the pathogenesis of BCR–ABL+ leukemia in mice

Oncogene volume 21, pages 8643–8651 (2002)Cite this article

Abstract

Animal models of BCR–ABL+ leukemias have provided important new knowledge about the molecular pathophysiology of these diseases, and answered questions that are difficult or impossible to address using BCR–ABL-expressing cell lines or primary Ph+ leukemia samples from patients. The power of mouse models lies in their ability to recapitulate precisely the phenotypes of BCR–ABL+ leukemias in vivo, but this comes at the price of significant complexity. Here I review recent studies of leukemias induced in mice by BCR–ABL with an emphasis on the intricate nature of these diseases and the need for careful pathological and molecular analysis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Anderson SM, Mladenovic J . 1996 Blood 87: 238–244

  • Andreasson P, Johansson B, Carlsson M, Jarlsfelt I, Fioretos T, Mitelman F, Hoglund M . 1997 Genes Chrom. Cancer 20: 299–304

  • Brunel V, Sainty D, Carbuccia N, Mozzicolacci M, Fernandez F, Simonetti J, Gabert J, Dubreuil P, Lafage-Pochitaloff M, Birg F . 1996 Leukemia 10: 2003

  • Carlesso N, Frank DA, Griffin JD . 1996 J. Exp. Med. 183: 811–820

  • Chung S-W, Wong PMC, Durkin H, Wu Y-S, Petersen J . 1991 Proc. Natl. Acad. Sci. USA 88: 1585–1589

  • Cortez D, Reuther G, Pendergast AM . 1997 Oncogene 15: 2333–2342

  • Daley G, Baltimore D . 1988 Proc. Natl. Acad. Sci. USA 85: 9312–9316

  • Daley GQ, Van Etten RA, Baltimore D . 1990 Science 247: 824–830

  • Daley GQ, Van Etten RA, Baltimore D . 1991 Proc. Natl. Acad. Sci. USA 88: 11335–11338

  • Dickens M, Rogers J, Cavanagh J, Raitano A, Xia Z, Halpern JR, Greenberg ME, Sawyers CL, Davis RJ . 1997 Science 277: 693–696

  • Elefanty AG, Cory S . 1992 Mol. Cell. Biol. 12: 1755–1763

  • Elefanty AG, Hariharan IK, Cory S . 1990 EMBO J. 9: 1069–1078

  • Era T, Witte ON . 2000 Proc. Natl. Acad. Sci. USA 97: 1737–1742

  • Franz WM, Berger P, Wang JYJ . 1989 EMBO J. 8: 137–147

  • Golub TR, Barker GF, Lovett M, Gilliland DG . 1994 Cell 77: 307–316

  • Golub TR, Goga A, Barker GF, Afar DEH, McLaughlin J, Bohlander SK, Rowley JD, Witte ON, Gilliland DG . 1996 Mol. Cell. Biol. 16: 4107–4116

  • Groopman JE, Golde DW . 1981 Ann. Int. Med. 94: 95–107

  • Gross AW, Ren R . 2000 Oncogene 19: 6286–6296

  • Han X, Wong PMC, Chung S-W . 1991 Proc. Natl. Acad. Sci. USA 88: 10129–10133

  • Hannemann JR, McManus DM, Kabarowski JHS, Wiedemann LW . 1998 Br. J. Haematol. 102: 475–485

  • Hariharan IK, Adams JM, Cory S . 1988 Oncogene Res. 3: 387–399

  • Ilaria RL, Van Etten RA . 1995 Blood 86: 3897–3904

  • Ilaria RL, Van Etten RA . 1996 J. Biol. Chem. 271: 31704–31710

  • Jackson P, Baltimore D . 1989 EMBO J. 8: 449–456

  • Jiang X, Lopez A, Holyoake T, Eaves A, Eaves C . 1999 Proc. Natl. Acad. Sci. USA 96: 12804–12809

  • Jousset C, Carron C, Boureux A, Quang CT, Oury C, Dusanter-Fourt I, Charon M, Levin J, Bernard O, Ghysdael J . 1997 EMBO J. 16: 69–82

  • Kelliher MA, McLaughlin J, Witte ON, Rosenberg N . 1990 Proc. Natl. Acad. Sci. USA 87: 6649–6653

  • Kelly LM, Liu Q, Kutok JL, Williams IR, Boulton CL, Gilliland DG . 2002 Blood 99: 310–318

  • Kipreos ET, Wang JYJ . 1992 Science 256: 382–385

  • Laneuville P, Heisterkamp N, Groffen J . 1991 Oncogene 6: 275–282

  • Li S, Gillessen S, Tomasson MH, Dranoff G, Gilliland DG, Van Etten RA . 2001 Blood 97: 1442–1450

  • Li S, Ilaria RL, Million RP, Daley GQ, Van Etten RA . 1999 J. Exp. Med. 189: 1399–1412

  • Liu J, Wu Y, Ma GZ, Lu D, Haataja L, Heisterkamp N, Groffen J, Arlinghaus RB . 1996 Mol. Cell. Biol. 16: 998–1005

  • Lugo TG, Pendergast A, Muller AJ, Witte ON . 1990 Science 247: 1079–1082

  • Lugo TG, Witte ON . 1989 Mol. Cell. Biol. 9: 1263–1270

  • Maru Y, Witte ON . 1991 Cell 67: 459–468

  • Mayer BJ, Jackson PK, Van Etten RA, Baltimore D . 1992 Mol. Cell. Biol. 12: 609–618

  • McLaughlin J, Chianese E, Witte ON . 1987 Proc. Natl. Acad. Sci. USA 84: 6558–6562

  • McWhirter JR, Galasso DL, Wang JYJ . 1993 Mol. Cell. Biol. 13: 7587–7595

  • McWhirter JR, Wang JYJ . 1993 EMBO J. 12: 1533–1546

  • Million RP, Aster J, Gilliland DG, Van Etten RA . 2002 Blood 99: 4568–4577

  • Million RP, Van Etten RA . 2000 Blood 96: 664–670

  • Nieborowska-Skorska M, Wasik MA, Slupianek A, Salomoni P, Kitamura T, Calabretta B, Skorski T . 1999 J. Exp. Med. 189: 1229–1242

  • Okuda K, Golub TG, Gilliland DG, Griffin JD . 1996 Oncogene 13: 1147–1152

  • Papadopoulos P, Ridge SA, Boucher CA, Stocking C, Wiedemann LM . 1995 Cancer Res. 55: 34–38

  • Pear WS, Miller JP, Xu L, Pui JC, Soffer B, Quackenbush RC, Pendergast AM, Bronson R, Aster JC, Scott ML, Baltimore D . 1998 Blood 92: 3780–3792

  • Pendergast AM, Gishizky ML, Havlik MH, Witte ON . 1993a Mol. Cell. Biol. 13: 1728–1736

  • Pendergast AM, Muller AJ, Havlik MH, Maru Y, Witte ON . 1991 Cell 66: 161–171

  • Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, Batzer A, Rabun KM, Der CJ, Schlessinger J, Gishizky ML . 1993b Cell 75: 175–185

  • Perlingeiro RC, Kyba M, Daley GQ . 2001 Development 128: 4597–4604

  • Peters DG, Klucher KM, Perlingeiro RC, Dessain SK, Koh EY, Daley GQ . 2001 Oncogene 20: 2636–2646

  • Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci PG, Arlinghaus R, Pawson T . 1994 EMBO J. 13: 764–773

  • Raitano AB, Halpern JR, Hambuch TM, Sawyers CL . 1995 Proc. Natl. Acad. Sci. USA 92: 11746–11750

  • Ren R, Zheng SY, Baltimore D . 1994 Genes Dev. 8: 783–795

  • Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin ASJ . 1998 Genes Dev. 12: 968–981

  • Roumiantsev S, de Aos I, Varticovski L, Ilaria RL, Van Etten RA . 2001 Blood 97: 4–13

  • Sawyers CL, Callahan W, Witte ON . 1992 Cell 70: 901–910

  • Sawyers CL, McLaughlin J, Witte ON . 1995 J. Exp. Med. 181: 307–313

  • Schwaller J, Frantsve J, Aster J, Williams IR, Tomasson MH, Ross TS, Van Rompey L, Peeters P, Van Etten RA, Ilaria Jr R, Marynen P, Gilliland DG . 1998 EMBO J. 17: 5321–5333

  • Scott ML, Van Etten RA, Daley GQ, Baltimore D . 1991 Proc. Natl. Acad. Sci. USA 88: 6506–6510

  • Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL . 1996 Oncogene 13: 247–254

  • Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen S-C, Zon G, Gewirtz AM, Perussia B, Calabretta B . 1995a Blood 86: 726–736

  • Skorski T, Nieborowska-Skorska M, Szczylik C, Kasnakaraj P, Perrotti D, Zon G, Gewirtz A, Perussia B, Calabretta B . 1995b Cancer Res. 55: 2275–2278

  • Tomasson MH, Sternberg DW, Williams IR, Carroll M, Cain D, Aster JC, Ilaria RL, Van Etten RA, Gilliland DG . 2000 J. Clin. Invest. 105: 423–432

  • Tomasson MH, Williams IR, Li S, Kutok J, Gillessen S, Dranoff G, Van Etten RA, Gilliland DG . 2001 Blood 97: 1435–1441

  • Van Etten RA . 2001 Curr. Oncol. Rep. 3: 228–237

  • Van Etten RA, Debnath J, Zhou H, Casasnovas JM . 1995 Oncogene 10: 1977–1988

  • Van Etten RA, Jackson PK, Baltimore D, Sanders MC, Matsudaira PT, Janmey PA . 1994 J. Cell Biol. 124: 325–340

  • van Limbergen H, Beverloo HB, van Drunen E, Janssens A, Hahlen K, Poppe B, van Roy N, Marynen P, de Paepe A, Slater R, Speleman F . 2001 Genes Chrom. Cancer 30: 274–282

  • Varticovski L, Daley G, Jackson P, Baltimore D, Cantley L . 1991 Mol. Cell. Biol. 11: 1107–1113

  • Voss J, Posern G, Hannemann JR, Wiedemann LM, Turhan AG, Poirel H, Bernard O, Adermann K, Kardinal C, Feller SM . 2000 Oncogene 19: 1684–1690

  • Wen S-T, Jackson PK, Van Etten RA . 1996 EMBO J. 15: 1583–1595

  • Wu Y, Liu J, Arlinghaus RB . 1998 Oncogene 16: 141–146

  • Zhang X, Ren R . 1998 Blood 92: 3829–3840

Download references

Acknowledgements

I thank the members of my laboratory, past and present, for their essential contributions to many of the papers discussed herein, and apologize to colleagues whose work was not cited due to space limitations. Special thanks to Drs George Daley, Warren Pear, and Gary Gilliland for many helpful discussions. This work was supported by NIH grant CA90576 and grants from the Leukemia and Lymphoma Society. RA Van Etten is a Scholar of the Leukemia and Lymphoma Society and the Carl and Margaret Walter Scholar in Blood Research at Harvard Medical School.

Author information

Authors and Affiliations

  1. The Center for Blood Research and Department of Genetics, Harvard Medical School, Boston, 02115, Massachusetts, MA, USA

    Richard A Van Etten

Authors
  1. Richard A Van Etten
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard A Van Etten.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Van Etten, R. Studying the pathogenesis of BCR–ABL+ leukemia in mice. Oncogene 21, 8643–8651 (2002). https://doi.org/10.1038/sj.onc.1206091

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206091

Keywords

This article is cited by

Search

Advanced search

Quick links